

Illinois Prescription Monitoring Program
Peer Review Committee
Annual Report

Illinois Department of Human Services (IDHS)
Division of Behavioral Health & Recovery (DBHR)¹
Illinois Prescription Monitoring Program (ILPMP)

FY26

¹ Effective July 1, 2025, IDHS's Divisions of Substance Use Prevention and Recovery and of Mental Health, were integrated into the single Division of Behavioral Health & Recovery.

Foreword

The Illinois Prescription Monitoring Program (ILPMP) is authorized by the Illinois Controlled Substance Act 720 ILCS 570/316 as a state-run electronic database that tracks the prescribing and dispensing of controlled substance prescription medications to patients in Illinois. The ILPMP compiles information from retail pharmacies regarding the dispensing of Schedule II-V controlled substance prescriptions and drugs of interest that are dispensed by retail pharmacies within Illinois. The purpose of the program is to strengthen the clinical review process and mitigate the potential diversion of controlled substance prescriptions.

Background

The ILPMP Advisory Committee is authorized to have a Peer Review Committee. The Peer Review Committee advises the ILPMP on matters related to the Advisory Committee's field of competence, reviews the professional performance of prescribers and dispensers, and develops communications directed to prescribers and dispensers. The deliberations, information, and communications of the Peer Review Committee are privileged and confidential.

The purpose of the Peer Review Committee is to establish a formal peer review of the professional performance of prescribers and dispensers. The Peer Review Committee periodically reviews the data available in the prescription monitoring database to identify providers who may be prescribing or dispensing outside the currently accepted standards of practice for their profession. Because the data available in the ILPMP database may not provide sufficient context for prescribing practices, the committee may request additional information regarding a provider's professional practice. Under 720 ILCS 570/320, the Peer Review Committee shall refer a prescriber or dispenser to the Illinois Department of Financial and Professional Regulation (IDFPR) if the prescriber or dispenser does not respond to three successive requests for information, does not provide a satisfactory explanation for the practices identified by the Committee, or does not sufficiently rectify the practices identified in the request for information.

Results FY26

In FY26, the Peer Review Committee met in closed session on April 21, 2026, and June 16, 2026. This review process was expanded to include pharmacies in addition to prescribers, creating a more comprehensive and balanced approach to oversight activities. This fiscal year also marked a period of transition, with resources dedicated to developing and implementing new initiatives designed to support future program objectives.

During the April 21, 2026, meeting, the committee discussed 55 pharmacies identified in this round that did not electronically report a Schedule II-V controlled substance prescription or other selected drugs, during January – June 2025. Based on the committee's findings, the committee made the following recommendations: 31 pharmacies provided sufficient information and required no further action; 24 pharmacies were referred to the ILPMP Pharmacy Compliance Team for additional education; and 0 pharmacies were referred to IDFPR.

During the June 16, 2026, meeting, no formal prescriber or pharmacy review cycle was conducted. The meeting provided an opportunity to update the committee members on enhancements to the peer review process and gather feedback prior to implementation.

Anonymous Referral Process

The purpose of the anonymous referral form is to provide a means of anonymously referring a prescriber believed to be prescribing outside of the currently accepted standard of practice. The Peer Review Committee is statutorily charged with identifying and reviewing data contained in the ILPMP database to determine if an investigation is warranted by IDFPR.

The ILPMP Peer Review Committee reviews referrals on a quarterly basis. Individuals submitting referrals are directed to contact IDFPR directly if the concern is urgent. In FY26, the ILPMP received 6 anonymous referrals. Based on the review, the committee made the following recommendations: 1 deemed sufficient and no further action required, 1 was referred to IDFPR for further investigation, and 4 referrals remain pending review.

Final Note

The Department is committed to ensuring that our interventions do not disrupt access to controlled substance prescribing for legitimate medical purposes. Additionally, the Department is committed to enhancing provider knowledge of clinical interventions through education and outreach.